Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years

OBJECTIVE: The efficacy and safety of abatacept in patients with juvenile idiopathic arthritis (JIA) who experienced an inadequate response to disease‐modifying antirheumatic drugs were previously established in a phase III study that included a 4‐month open‐label lead‐in period, a 6‐month double‐bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovell, Daniel J., Ruperto, Nicolino, Mouy, Richard, Paz, Eliana, Rubio‐Pérez, Nadina, Silva, Clovis A., Abud‐Mendoza, Carlos, Burgos‐Vargas, Ruben, Gerloni, Valeria, Melo‐Gomes, Jose A., Saad‐Magalhaes, Claudia, Chavez‐Corrales, J., Huemer, Christian, Kivitz, Alan, Blanco, Francisco J., Foeldvari, Ivan, Hofer, Michael, Huppertz, Hans‐Iko, Job Deslandre, Chantal, Minden, Kirsten, Punaro, Marilynn, Block, Alan J., Giannini, Edward H., Martini, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Pediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054936/
https://www.ncbi.nlm.nih.gov/pubmed/26097215
http://dx.doi.org/10.1002/art.39234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054936/
https://www.ncbi.nlm.nih.gov/pubmed/26097215
http://dx.doi.org/10.1002/art.39234

Ejemplares similares